Must Buy Stocks: BIONTECH (BNTX), PFIZER (PFE), & VIATRIS (VTRS)

Contact Us
Susan Chua
Che San Building 10 Pottinger Street
Central
Hong Kong 999077 
india
Phone:+85258081473
info@primebrightinvest.com

There is one advantage to large market declines. It’s actually a fantastic thing. They give investors an opportunity to purchase equities at a discounted price.
Here’s why BioNTech (BNTX), Pfizer (PFE) and Viatris Inc. (VTRS) were chosen.

BIONTECH SE (BNTX)

Investors can sometimes underestimate a stock that appears to be punching above its weight class, assuming that it will struggle in the future. BNTX projected a price-to-earnings ratio of roughly 3.8 which indicates that investors may not be paying attention to the growing firm.

Those investors, however, would be incorrect. BNTX appears to have a strong collaboration with PFE, the world’s largest pharmaceutical company. The two firms collaborated to develop BNT162b2, a highly effective COVID-19 vaccine. They’re also developing a shingles vaccine using messenger RNA (mRNA) technology, with clinical trials set to begin later this year.

In addition to the shingles vaccine, clinical trials for malaria, TB, and the herpes simplex virus will begin soon (type 2). BNTX also has a promising cancer pipeline with 20 clinical studies now underway.

PFIZER INC. (PFE)

PFE, unlike BNTX, isn’t completely reliant on a single product to generate revenue. At least nine medications or vaccines in the company’s pipeline are expected to generate $1 billion in sales this year. PFE seems to be on track to make over $100 billion in revenue by 2022. That would be the highest amount of money ever earned by a pharmaceutical business.

Granted, PFE’s current growth is mostly driven by its COVID-19 vaccine and Paxlovid, an oral COVID-19 treatment. Even without these initiatives, the business intends to expand adjusted profits per share into the double digits through 2025.

VIATRIS INC. (VTRS)

VTRS may have been overlooked by the market for good cause. The business is faced with a number of difficulties, including slow revenue growth.
There are, however, grounds to be positive. VTRS is still one of the world’s largest generic medicine makers. Patents do not help the company’s goods but it is increasingly attempting to promote sophisticated generics. These items are less competitive on the market and can help VTRS increase their income in upcoming years.

Meanwhile, the firm is working to enhance its financial sheet, particularly by reducing debt. By the end of 2022, VTRS hopes to have paid off $2 billion in debt. It is currently on pace to meet that objective.

For more latest news in US stock market you may also visit us at Prime Bright Investment Limited through our website or contact us via email.